Pub Date : 2025-01-16eCollection Date: 2025-01-01DOI: 10.1177/25158414241311256
Jaime Tejedor, Francisco J Gutiérrez-Carmona
Background: Small conjunctival incision size is desirable in strabismus surgery under topical anesthesia.
Objective: To study the feasibility and tolerability of a small bulbar conjunctival incision (SB).
Design: Non-randomized feasibility pilot study.
Methods: After applying a 5-0 PGA (polyglycolic acid) traction suture, we did a 3-4 mm single conjunctival incision posterior and parallel to the rectus muscle insertion. A hang-back recession was done (6-0 PGA suture), and the conjunctiva closed (8-0 PGA suture). The outcome measures were feasibility, tolerability, and motor result.
Results: Twenty-five patients were included. The median pain scale score was 3/10, and the satisfaction Net Promoter Score was 72. Mean duration of a recession was 12 min (range: 9-14 min). Mean duration of inflammatory signs and hemorrhage were 2.2 days (95% CI, 1.4-2.9), and 8.5 days (95% CI, 7.1-9.9), respectively. Distance deviation at 2 months was 3.1 Prism Diopters (95% CI, 1.5-4.5).
Conclusion: SB is feasible and well tolerated for extraocular rectus muscle surgery.
{"title":"Single minimal conjunctival incision for rectus muscles: a pilot feasibility study.","authors":"Jaime Tejedor, Francisco J Gutiérrez-Carmona","doi":"10.1177/25158414241311256","DOIUrl":"https://doi.org/10.1177/25158414241311256","url":null,"abstract":"<p><strong>Background: </strong>Small conjunctival incision size is desirable in strabismus surgery under topical anesthesia.</p><p><strong>Objective: </strong>To study the feasibility and tolerability of a small bulbar conjunctival incision (SB).</p><p><strong>Design: </strong>Non-randomized feasibility pilot study.</p><p><strong>Methods: </strong>After applying a 5-0 PGA (polyglycolic acid) traction suture, we did a 3-4 mm single conjunctival incision posterior and parallel to the rectus muscle insertion. A hang-back recession was done (6-0 PGA suture), and the conjunctiva closed (8-0 PGA suture). The outcome measures were feasibility, tolerability, and motor result.</p><p><strong>Results: </strong>Twenty-five patients were included. The median pain scale score was 3/10, and the satisfaction Net Promoter Score was 72. Mean duration of a recession was 12 min (range: 9-14 min). Mean duration of inflammatory signs and hemorrhage were 2.2 days (95% CI, 1.4-2.9), and 8.5 days (95% CI, 7.1-9.9), respectively. Distance deviation at 2 months was 3.1 Prism Diopters (95% CI, 1.5-4.5).</p><p><strong>Conclusion: </strong>SB is feasible and well tolerated for extraocular rectus muscle surgery.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414241311256"},"PeriodicalIF":2.3,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-16eCollection Date: 2025-01-01DOI: 10.1177/25158414241311064
Daniel J Hu, Sophia Ghauri, Magdalena G Krzystolik
Objective: To perform a systematic literature review analyzing visual outcomes of immediate, early, and delayed vitrectomy in the treatment of acute endophthalmitis after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections.
Methods: We conducted a literature search using the Ovid Medline, Embase.com, and Web of Science databases, and relevant articles were selected from original English papers published from 2005 to 2021. Inclusion criteria were studies reporting cases of acute post-anti-VEGF endophthalmitis, defined as occurring within 6 weeks of injection treatment. Exclusion criteria were pediatric cases and cases explicitly reported to be caused by injections of contaminated drugs. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal tool for case reports and case series. The study dataset for descriptive and statistical analysis comprised patient-level data extracted from included studies. The timing of vitrectomy compared were defined as (1) immediate vitrectomy as occurring within 24 h of endophthalmitis diagnosis; (2) early vitrectomy as occurring between 24 and 48 h of endophthalmitis diagnosis; (3) late vitrectomy as occurring after 48 h of endophthalmitis diagnosis. Primary outcome was final visual acuity following treatment with vitrectomy.
Results: Twenty-five articles were published that met our inclusion and exclusion criteria for a total of 86 cases. Thirty-seven were immediate vitrectomy, 25 were early, and 24 were late vitrectomy treatment groups, respectively. We observed differences in final visual outcomes and in improvement from diagnosis to final visual acuity, with patients receiving immediate and late vitrectomy to have better final visual outcomes than those patients receiving early vitrectomy (p < 0.005).
Conclusion: Our results show that there may be an association between time to vitrectomy and visual outcomes. Immediate and late vitrectomy treatment groups had better visual outcomes than the early group. Our results were limited by the reliance on case reports and series and the paucity of data available specifying the timing of vitrectomy. Additional research is necessary to elucidate the effects of treatment timing in patients with endophthalmitis following anti-VEGF injection.
目的:对玻璃体内注射抗血管内皮生长因子(anti-VEGF)后立即、早期和延迟玻璃体切除术治疗急性眼内炎的视力结果进行系统的文献回顾分析。方法:使用Ovid Medline、Embase.com和Web of Science数据库进行文献检索,选取2005 - 2021年发表的英文原版论文中的相关文章。纳入标准是报告急性抗vegf后眼内炎病例的研究,定义为在注射治疗后6周内发生。排除标准是儿科病例和明确报告因注射受污染药物引起的病例。使用案例报告和案例系列的乔安娜布里格斯研究所关键评估工具评估偏倚风险。用于描述性和统计分析的研究数据集包括从纳入研究中提取的患者水平数据。玻璃体切除术时间的比较定义为:(1)在眼内炎诊断后24小时内立即进行玻璃体切除术;(2)在眼内炎诊断后24 ~ 48小时内进行早期玻璃体切除术;(3)诊断为眼内炎48小时后进行玻璃体切除术。主要结果为玻璃体切除术后的最终视力。结果:共有25篇文章符合我们的纳入和排除标准,共86例。即刻玻璃体切除术治疗组37例,早期玻璃体切除术治疗组25例,晚期玻璃体切除术治疗组24例。我们观察到最终视力结果的差异以及从诊断到最终视力的改善,立即和晚期玻璃体切除术患者的最终视力结果优于早期玻璃体切除术患者(p结论:我们的结果表明玻璃体切除术时间与视力结果可能存在关联。即刻和晚期玻璃体切除术治疗组视力优于早期治疗组。我们的结果受限于病例报告和系列的依赖,以及指定玻璃体切除术时间的可用数据的缺乏。需要进一步的研究来阐明抗vegf注射后治疗时间对眼内炎患者的影响。
{"title":"Timing of vitrectomy for treatment of endophthalmitis after intravitreal anti-VEGF injection: a systematic literature review of case reports and series.","authors":"Daniel J Hu, Sophia Ghauri, Magdalena G Krzystolik","doi":"10.1177/25158414241311064","DOIUrl":"https://doi.org/10.1177/25158414241311064","url":null,"abstract":"<p><strong>Objective: </strong>To perform a systematic literature review analyzing visual outcomes of immediate, early, and delayed vitrectomy in the treatment of acute endophthalmitis after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections.</p><p><strong>Methods: </strong>We conducted a literature search using the Ovid Medline, Embase.com, and Web of Science databases, and relevant articles were selected from original English papers published from 2005 to 2021. Inclusion criteria were studies reporting cases of acute post-anti-VEGF endophthalmitis, defined as occurring within 6 weeks of injection treatment. Exclusion criteria were pediatric cases and cases explicitly reported to be caused by injections of contaminated drugs. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal tool for case reports and case series. The study dataset for descriptive and statistical analysis comprised patient-level data extracted from included studies. The timing of vitrectomy compared were defined as (1) immediate vitrectomy as occurring within 24 h of endophthalmitis diagnosis; (2) early vitrectomy as occurring between 24 and 48 h of endophthalmitis diagnosis; (3) late vitrectomy as occurring after 48 h of endophthalmitis diagnosis. Primary outcome was final visual acuity following treatment with vitrectomy.</p><p><strong>Results: </strong>Twenty-five articles were published that met our inclusion and exclusion criteria for a total of 86 cases. Thirty-seven were immediate vitrectomy, 25 were early, and 24 were late vitrectomy treatment groups, respectively. We observed differences in final visual outcomes and in improvement from diagnosis to final visual acuity, with patients receiving immediate and late vitrectomy to have better final visual outcomes than those patients receiving early vitrectomy (<i>p</i> < 0.005).</p><p><strong>Conclusion: </strong>Our results show that there may be an association between time to vitrectomy and visual outcomes. Immediate and late vitrectomy treatment groups had better visual outcomes than the early group. Our results were limited by the reliance on case reports and series and the paucity of data available specifying the timing of vitrectomy. Additional research is necessary to elucidate the effects of treatment timing in patients with endophthalmitis following anti-VEGF injection.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414241311064"},"PeriodicalIF":2.3,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143011977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-16eCollection Date: 2025-01-01DOI: 10.1177/25158414241305500
Nathalie Skovgaard Eriksen, Nabi Mousavi, Yousif Subhi, Torben Lykke Sørensen, Marie Krogh Nielsen
Background: Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss among the elderly. The prevalence and detailed characteristics of Charles Bonnet syndrome (CBS) remain largely unexplored in patients with geographic atrophy (GA) secondary to AMD.
Objectives: To investigate the prevalence and characteristics of CBS in patients with GA secondary to AMD.
Design: Prospective cross-sectional study.
Methods: A total of 149 patients with GA secondary to AMD were previously screened and examined for clinical studies. These patients were then prospective contacted by telephone for this study, and 120 patients responded and agreed to do an interview on symptoms of CBS. All with CBS were inquired about detailed characteristics of their hallucinations.
Results: Patients with GA secondary to AMD were aged 82.1 ± 6.2 years and 62% were of female biological sex. The prevalence of CBS was 25 in 120 (20.8%). Thirteen (52%) of those with CBS were not previously informed of the disease. We found no difference between those with and without CBS in terms of age, biological sex, hearing difficulties, whether living alone or with others, co-morbidity of psychiatric or neurological diseases, or psychotropic use. Characteristics of the visual hallucinations were reported to occur at various frequencies from daily to less than monthly, occur during various times of the day, and almost always last minutes at most. Ten in 25 (40%) had not told anyone of having CBS.
Conclusion: One in five with GA has CBS, which ranks GA as an eye disease with one of the highest reported prevalences of CBS. The condition presents with a significant variation across the patient group. A very large proportion of those with CBS were not informed of the disease and had never told anyone of their condition by their own initiative.
{"title":"Charles Bonnet syndrome in patients with geographic atrophy secondary to age-related macular degeneration: a cross-sectional study.","authors":"Nathalie Skovgaard Eriksen, Nabi Mousavi, Yousif Subhi, Torben Lykke Sørensen, Marie Krogh Nielsen","doi":"10.1177/25158414241305500","DOIUrl":"https://doi.org/10.1177/25158414241305500","url":null,"abstract":"<p><strong>Background: </strong>Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss among the elderly. The prevalence and detailed characteristics of Charles Bonnet syndrome (CBS) remain largely unexplored in patients with geographic atrophy (GA) secondary to AMD.</p><p><strong>Objectives: </strong>To investigate the prevalence and characteristics of CBS in patients with GA secondary to AMD.</p><p><strong>Design: </strong>Prospective cross-sectional study.</p><p><strong>Methods: </strong>A total of 149 patients with GA secondary to AMD were previously screened and examined for clinical studies. These patients were then prospective contacted by telephone for this study, and 120 patients responded and agreed to do an interview on symptoms of CBS. All with CBS were inquired about detailed characteristics of their hallucinations.</p><p><strong>Results: </strong>Patients with GA secondary to AMD were aged 82.1 ± 6.2 years and 62% were of female biological sex. The prevalence of CBS was 25 in 120 (20.8%). Thirteen (52%) of those with CBS were not previously informed of the disease. We found no difference between those with and without CBS in terms of age, biological sex, hearing difficulties, whether living alone or with others, co-morbidity of psychiatric or neurological diseases, or psychotropic use. Characteristics of the visual hallucinations were reported to occur at various frequencies from daily to less than monthly, occur during various times of the day, and almost always last minutes at most. Ten in 25 (40%) had not told anyone of having CBS.</p><p><strong>Conclusion: </strong>One in five with GA has CBS, which ranks GA as an eye disease with one of the highest reported prevalences of CBS. The condition presents with a significant variation across the patient group. A very large proportion of those with CBS were not informed of the disease and had never told anyone of their condition by their own initiative.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414241305500"},"PeriodicalIF":2.3,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143011955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-16eCollection Date: 2025-01-01DOI: 10.1177/25158414241311078
Andrea Cusumano, Robin Ross, Benedetto Falsini, Marco Lombardo
Diabetic retinopathy and retinal vein occlusion represent two prevalent vision-threatening retinal diseases. Retinal laser therapy still plays an important role in treating these conditions, but its successful administration often requires referral to specialized centers and retina experts. It is, therefore, essential to develop a new treatment methodology that enables patients to benefit from the expertise of specialists from reference centers. For this purpose, we investigated the feasibility of teleguided photocoagulation conducted across continents to determine if different ophthalmologists can consensually devise and safely execute treatment plans remotely. Two patients from Italy (Europe) with diabetic retinopathy and one from Arizona (USA) with central retinal vein occlusion underwent retinal photocoagulation using Navilas® 577s with remote teleguidance from the corresponding continental counterpart. The process included remote planning and execution, supported by an audio connection for real-time communication. Teletreatment success criteria included treatment plan completion, patient tolerance, remote connection stability, and technical quality. All treatments have been successfully performed with accurate spot application and no technical issues. Follow-ups at three weeks confirmed positive outcomes for each patient. Remote teleguided retinal photocoagulation appears feasible, offering a promising tool for global collaborations in retina care and potential benefits to regions with limited access to expert supervision.
{"title":"Teleguided photocoagulation treatments across continents with a remotely programmed laser for retinal diseases.","authors":"Andrea Cusumano, Robin Ross, Benedetto Falsini, Marco Lombardo","doi":"10.1177/25158414241311078","DOIUrl":"https://doi.org/10.1177/25158414241311078","url":null,"abstract":"<p><p>Diabetic retinopathy and retinal vein occlusion represent two prevalent vision-threatening retinal diseases. Retinal laser therapy still plays an important role in treating these conditions, but its successful administration often requires referral to specialized centers and retina experts. It is, therefore, essential to develop a new treatment methodology that enables patients to benefit from the expertise of specialists from reference centers. For this purpose, we investigated the feasibility of teleguided photocoagulation conducted across continents to determine if different ophthalmologists can consensually devise and safely execute treatment plans remotely. Two patients from Italy (Europe) with diabetic retinopathy and one from Arizona (USA) with central retinal vein occlusion underwent retinal photocoagulation using Navilas<sup>®</sup> 577s with remote teleguidance from the corresponding continental counterpart. The process included remote planning and execution, supported by an audio connection for real-time communication. Teletreatment success criteria included treatment plan completion, patient tolerance, remote connection stability, and technical quality. All treatments have been successfully performed with accurate spot application and no technical issues. Follow-ups at three weeks confirmed positive outcomes for each patient. Remote teleguided retinal photocoagulation appears feasible, offering a promising tool for global collaborations in retina care and potential benefits to regions with limited access to expert supervision.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"17 ","pages":"25158414241311078"},"PeriodicalIF":2.3,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-10eCollection Date: 2024-01-01DOI: 10.1177/25158414241302891
Brian Church, Pierre Wassermann
Background: Selective laser trabeculoplasty (SLT) is an effective long-term option for the treatment of open-angle glaucoma.
Objectives: To investigate the real-world efficacy and safety of SLT with the Zeiss VISULAS green laser in medically treated primary open-angle glaucoma (POAG).
Design: Retrospective, single-center study.
Methods: POAG patients ⩾18 years of age on at least one antiglaucoma medication prior to the procedure, who underwent SLT with the Zeiss VISULAS green laser (Carl Zeiss Meditec, Jena, Germany). Medications were terminated or reinstated at subsequent follow-ups depending on the intraocular pressure (IOP) control. The primary efficacy outcome measures were mean reduction in glaucoma medications and mean reduction in IOP at 3, 6, and 12 months compared to baseline. Safety outcomes were intra- or post-procedural complications.
Results: One hundred fifty-six eyes of 156 patients, aged 66.5 ± 13.2 years, were recruited. The mean number of medications was reduced from 2.3 ± 1.0 at baseline to 0.8 ± 1.1 and 0.8 ± 1.2 at 3- and 6 months, respectively (p < 0.001). Despite the reduction of medications, the mean IOP (mmHg) was reduced from 16.6 ± 3.10 at baseline to 15.4 ± 3.82 at 3 months (n = 156) and 15.1 ± 3.30 at 6 months (n = 140) (p < 0.001). IOP reduction ⩾20% was observed in 28.8% of patients at 3 months and 27.9% of patients at 6 months. In the 12-month follow-up group (n = 22), mean medications and IOP (mmHg) at baseline were 2.3 ± 0.9 and 16.0 ± 2.80, respectively, which decreased to 0.9 ± 1.1 (p < 0.001) and 14.5 ± 1.92 (p = 0.103), respectively. At 3- and 6-month post-procedure, 59.6% of patients and 60% of patients, respectively, were medication-free compared to none at baseline. At 6 months, 69.3% of patients maintained IOP lower than or equal to pre-procedure IOP on fewer medications compared to baseline. No vision-threatening intra- or post-procedure complications were noted.
Conclusion: SLT with the Zeiss VISULAS green laser resulted in a clinically and statistically significant reduction in number of medications needed for IOP control. The procedure had a good safety profile similar to that described in the literature for SLT, with no vision-threatening complications.
背景:选择性激光小梁成形术(SLT)是治疗开角型青光眼的一种有效的长期选择。目的:探讨蔡司VISULAS绿色激光SLT治疗原发性开角型青光眼(POAG)的疗效和安全性。设计:回顾性、单中心研究。方法:在手术前使用至少一种抗青光眼药物的年龄大于或等于18岁的POAG患者,使用蔡司VISULAS绿色激光器(卡尔蔡司Meditec,耶拿,德国)进行SLT。根据眼压(IOP)的控制情况,在随后的随访中终止或恢复药物治疗。主要疗效指标是与基线相比,青光眼药物的平均减少量和IOP在3、6和12个月的平均减少量。安全性结果为术中或术后并发症。结果:156例患者156只眼,年龄66.5±13.2岁。平均用药次数从基线时的2.3±1.0次分别减少到3个月和6个月时的0.8±1.1次和0.8±1.2次(p n = 156)和6个月时的15.1±3.30次(n = 140) (p n = 22),平均用药次数和IOP (mmHg)分别从2.3±0.9和16.0±2.80次减少到0.9±1.1次(p p = 0.103)。在术后3个月和6个月,分别有59.6%的患者和60%的患者无药物治疗,而基线时无药物治疗。在6个月时,与基线相比,使用较少药物的69.3%患者IOP低于或等于术前IOP。手术中或术后未见危及视力的并发症。结论:蔡司VISULAS绿色激光的SLT在临床上和统计学上显著减少了IOP控制所需的药物数量。该手术具有良好的安全性,与文献中描述的SLT相似,没有视力威胁并发症。
{"title":"Real-world results of the Zeiss selective laser trabeculoplasty in adult South African primary open-angle glaucoma patients.","authors":"Brian Church, Pierre Wassermann","doi":"10.1177/25158414241302891","DOIUrl":"10.1177/25158414241302891","url":null,"abstract":"<p><strong>Background: </strong>Selective laser trabeculoplasty (SLT) is an effective long-term option for the treatment of open-angle glaucoma.</p><p><strong>Objectives: </strong>To investigate the real-world efficacy and safety of SLT with the Zeiss VISULAS green laser in medically treated primary open-angle glaucoma (POAG).</p><p><strong>Design: </strong>Retrospective, single-center study.</p><p><strong>Methods: </strong>POAG patients ⩾18 years of age on at least one antiglaucoma medication prior to the procedure, who underwent SLT with the Zeiss VISULAS green laser (Carl Zeiss Meditec, Jena, Germany). Medications were terminated or reinstated at subsequent follow-ups depending on the intraocular pressure (IOP) control. The primary efficacy outcome measures were mean reduction in glaucoma medications and mean reduction in IOP at 3, 6, and 12 months compared to baseline. Safety outcomes were intra- or post-procedural complications.</p><p><strong>Results: </strong>One hundred fifty-six eyes of 156 patients, aged 66.5 ± 13.2 years, were recruited. The mean number of medications was reduced from 2.3 ± 1.0 at baseline to 0.8 ± 1.1 and 0.8 ± 1.2 at 3- and 6 months, respectively (<i>p</i> < 0.001). Despite the reduction of medications, the mean IOP (mmHg) was reduced from 16.6 ± 3.10 at baseline to 15.4 ± 3.82 at 3 months (<i>n</i> = 156) and 15.1 ± 3.30 at 6 months (<i>n</i> = 140) (<i>p</i> < 0.001). IOP reduction ⩾20% was observed in 28.8% of patients at 3 months and 27.9% of patients at 6 months. In the 12-month follow-up group (<i>n</i> = 22), mean medications and IOP (mmHg) at baseline were 2.3 ± 0.9 and 16.0 ± 2.80, respectively, which decreased to 0.9 ± 1.1 (<i>p</i> < 0.001) and 14.5 ± 1.92 (<i>p</i> = 0.103), respectively. At 3- and 6-month post-procedure, 59.6% of patients and 60% of patients, respectively, were medication-free compared to none at baseline. At 6 months, 69.3% of patients maintained IOP lower than or equal to pre-procedure IOP on fewer medications compared to baseline. No vision-threatening intra- or post-procedure complications were noted.</p><p><strong>Conclusion: </strong>SLT with the Zeiss VISULAS green laser resulted in a clinically and statistically significant reduction in number of medications needed for IOP control. The procedure had a good safety profile similar to that described in the literature for SLT, with no vision-threatening complications.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"16 ","pages":"25158414241302891"},"PeriodicalIF":2.3,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-06eCollection Date: 2024-01-01DOI: 10.1177/25158414241302065
Kwame A Baffour-Awuah, Holly Bridge, Hilary Engward, Robert C MacKinnon, I Betina Ip, Jasleen K Jolly
Charles Bonnet syndrome (CBS) is a condition characterised by visual hallucinations of varying complexity on a background of vision loss. CBS research has gained popularity only in recent decades, despite evidence dating back to 1760. Knowledge of CBS among both the patient and professional populations unfortunately remains poor, and little is known of its underlying pathophysiology. CBS parallels two other better-known conditions that occur as a result of sensory loss: phantom limb syndrome (PLS) (aberrant sensation of the presence of a missing limb) and tinnitus (aberrant sensation of sound). As 'phantom' conditions, CBS, PLS and tinnitus share sensory loss as a precipitating factor, and, as subjective perceptual phenomena, face similar challenges to investigations. Thus far, these conditions have been studied separately from each other. This review aims to bridge the conceptual gap between CBS, PLS and tinnitus and seek common lessons between them. It considers the current knowledge base of CBS and explores the extent to which an understanding of PLS and tinnitus could provide valuable insights into the pathology of CBS (including the roles of cortical reorganisation, emotional and cognitive factors), and towards identifying effective potential management for CBS.
{"title":"The missing pieces: an investigation into the parallels between Charles Bonnet, phantom limb and tinnitus syndromes.","authors":"Kwame A Baffour-Awuah, Holly Bridge, Hilary Engward, Robert C MacKinnon, I Betina Ip, Jasleen K Jolly","doi":"10.1177/25158414241302065","DOIUrl":"10.1177/25158414241302065","url":null,"abstract":"<p><p>Charles Bonnet syndrome (CBS) is a condition characterised by visual hallucinations of varying complexity on a background of vision loss. CBS research has gained popularity only in recent decades, despite evidence dating back to 1760. Knowledge of CBS among both the patient and professional populations unfortunately remains poor, and little is known of its underlying pathophysiology. CBS parallels two other better-known conditions that occur as a result of sensory loss: phantom limb syndrome (PLS) (aberrant sensation of the presence of a missing limb) and tinnitus (aberrant sensation of sound). As 'phantom' conditions, CBS, PLS and tinnitus share sensory loss as a precipitating factor, and, as subjective perceptual phenomena, face similar challenges to investigations. Thus far, these conditions have been studied separately from each other. This review aims to bridge the conceptual gap between CBS, PLS and tinnitus and seek common lessons between them. It considers the current knowledge base of CBS and explores the extent to which an understanding of PLS and tinnitus could provide valuable insights into the pathology of CBS (including the roles of cortical reorganisation, emotional and cognitive factors), and towards identifying effective potential management for CBS.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"16 ","pages":"25158414241302065"},"PeriodicalIF":2.3,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11624543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142802245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-04eCollection Date: 2024-01-01DOI: 10.1177/25158414241302871
Jeremy Jia Hao Chan, Pak Wing Leung, Helena Kilgour, Panagiotis Dervenis
The integration of artificial intelligence (AI) in healthcare, particularly in the domain of facial processing tasks, has witnessed substantial growth in the 21st century. However, this requires sufficient appraisal for clinicians and researchers to adequately understand nomenclature and key concepts commonly used in this field. This article aims to elucidate the diverse applications of facial processing tasks, such as facial landmark extraction, face detection, face tracking, facial expression recognition and action unit detection, and their relevance to ophthalmology and other medical specialties. The keywords 'ophthalmology', 'facial artificial intelligence', 'facial recognition' and 'periorbital measurements' were used on PubMed and Ovid, between September 2012 and September 2022, to identify and screen for eligible articles. Studies reporting on human patients in ophthalmology, plastic, maxillofacial and cosmetic surgery with ocular lesions whose facial biometrics were processed by AI and written in the English language were included. A total of 291 and 513 articles were identified on PubMed and Ovid respectively. Twenty articles were included for analysis in this literature review after duplicates, inaccessible articles and articles without full manuscripts were excluded. Although fully automated algorithms can share the workload in healthcare systems and relieve strains on manpower, rigorous testing is crucial, followed by the challenges of convincing management bodies that it would work in reality, coupled with the costs of implementing specialised functional hardware and software. While patients have a valid concern that it would reduce physical contact with clinicians, it is important for clinicians not to replace clinical decision-making with AI alone.
{"title":"Facial artificial intelligence in ophthalmology and medicine: fundamental and transformative applications.","authors":"Jeremy Jia Hao Chan, Pak Wing Leung, Helena Kilgour, Panagiotis Dervenis","doi":"10.1177/25158414241302871","DOIUrl":"10.1177/25158414241302871","url":null,"abstract":"<p><p>The integration of artificial intelligence (AI) in healthcare, particularly in the domain of facial processing tasks, has witnessed substantial growth in the 21st century. However, this requires sufficient appraisal for clinicians and researchers to adequately understand nomenclature and key concepts commonly used in this field. This article aims to elucidate the diverse applications of facial processing tasks, such as facial landmark extraction, face detection, face tracking, facial expression recognition and action unit detection, and their relevance to ophthalmology and other medical specialties. The keywords 'ophthalmology', 'facial artificial intelligence', 'facial recognition' and 'periorbital measurements' were used on PubMed and Ovid, between September 2012 and September 2022, to identify and screen for eligible articles. Studies reporting on human patients in ophthalmology, plastic, maxillofacial and cosmetic surgery with ocular lesions whose facial biometrics were processed by AI and written in the English language were included. A total of 291 and 513 articles were identified on PubMed and Ovid respectively. Twenty articles were included for analysis in this literature review after duplicates, inaccessible articles and articles without full manuscripts were excluded. Although fully automated algorithms can share the workload in healthcare systems and relieve strains on manpower, rigorous testing is crucial, followed by the challenges of convincing management bodies that it would work in reality, coupled with the costs of implementing specialised functional hardware and software. While patients have a valid concern that it would reduce physical contact with clinicians, it is important for clinicians not to replace clinical decision-making with AI alone.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"16 ","pages":"25158414241302871"},"PeriodicalIF":2.3,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11618896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-28eCollection Date: 2024-01-01DOI: 10.1177/25158414241302879
Joseph Hu, Chao-Chien Hu
Congenital aniridia is a rare genetic eye disorder often associated with PAX6 gene mutations, leading to complex ocular manifestations, including aniridia-associated keratopathy (AAK) and cataracts. The surgical management of cataracts in these patients is particularly challenging due to severe corneal opacities, which obscure key surgical steps such as capsulorhexis and phacoemulsification. This report presents two cases of congenital aniridia with severe AAK, in which chandelier retroillumination-assisted cataract surgery was employed. This technique, typically used in vitreous surgery, provided enhanced visualization of the lens through posterior segment illumination, facilitating successful cataract extraction and intraocular lens implantation. Both patients showed significant postoperative improvement in visual acuity. These cases demonstrate the feasibility and effectiveness of chandelier retroillumination-assisted cataract surgery in patients with congenital aniridia complicated by severe corneal opacity.
{"title":"Chandelier retroillumination-assisted cataract surgery in two cases of congenital aniridia with severe aniridia-associated keratopathy: case series.","authors":"Joseph Hu, Chao-Chien Hu","doi":"10.1177/25158414241302879","DOIUrl":"https://doi.org/10.1177/25158414241302879","url":null,"abstract":"<p><p>Congenital aniridia is a rare genetic eye disorder often associated with PAX6 gene mutations, leading to complex ocular manifestations, including aniridia-associated keratopathy (AAK) and cataracts. The surgical management of cataracts in these patients is particularly challenging due to severe corneal opacities, which obscure key surgical steps such as capsulorhexis and phacoemulsification. This report presents two cases of congenital aniridia with severe AAK, in which chandelier retroillumination-assisted cataract surgery was employed. This technique, typically used in vitreous surgery, provided enhanced visualization of the lens through posterior segment illumination, facilitating successful cataract extraction and intraocular lens implantation. Both patients showed significant postoperative improvement in visual acuity. These cases demonstrate the feasibility and effectiveness of chandelier retroillumination-assisted cataract surgery in patients with congenital aniridia complicated by severe corneal opacity.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"16 ","pages":"25158414241302879"},"PeriodicalIF":2.3,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11605765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Managing recurrent pterygium combined with symblepharon presents significant challenges in ophthalmology. Clinicians aim to reconstruct the ocular surface, alleviate eye movement restrictions, and minimize recurrence risks.
Objective: Evaluation of efficacy and safety of continuous blanket sutures (CBS) for fixation of large autologous conjunctival grafts in patients with severe recurrent pterygium with symblepharon.
Methods: Retrospective, observational case series. Thirty-nine patients (40 eyes) were included, all with severe recurrent pterygium with symblepharon. During surgery, CBS was employed to affix large autologous conjunctival grafts to the exposed sclera, aiming to restore the ocular surface to smoothness as much as possible. All patients were followed up for more than one year. Main outcome measures include the rate of recurrence, improvement of eye movement, and intraoperative and postoperative complications.
Results: Nearly all patients exhibited a smooth ocular surface and largely restored physiological structures during the follow-up period. There were no graft loss or contraction cases until the last follow-up, with only three eyes experiencing a pterygium recurrence (recurrence rate 7.5%, 3/40). Preoperative eye movement limitations improved significantly from 2.10 ± 0.71 (range 1-3) to 0.33 ± 0.53 (range 0-2; p < 0.001) post-surgery. Other postoperative complications included varying degrees of corneal scarring and a single instance of conjunctival granulomatous hyperplasia (1 eye, 2.5%).
Conclusion: When addressing severe recurrent pterygium with Symblepharon, using CBS to secure large autologous conjunctival grafts during surgery can achieve favorable postoperative outcomes. This surgical method is safe and feasible and effectively rebuilds a smooth ocular surface, improves the appearance of the ocular surface, and reduces the recurrence rate of pterygium after excision.
{"title":"The efficacy and safety of continuous blanket suture for severe recurrent pterygium with symblepharon.","authors":"Huixiang Ma, Jiahui Shen, Xuhao Chen, Xianfeng Ye, Shuxia Xu, Zongduan Zhang","doi":"10.1177/25158414241294191","DOIUrl":"https://doi.org/10.1177/25158414241294191","url":null,"abstract":"<p><strong>Background: </strong>Managing recurrent pterygium combined with symblepharon presents significant challenges in ophthalmology. Clinicians aim to reconstruct the ocular surface, alleviate eye movement restrictions, and minimize recurrence risks.</p><p><strong>Objective: </strong>Evaluation of efficacy and safety of continuous blanket sutures (CBS) for fixation of large autologous conjunctival grafts in patients with severe recurrent pterygium with symblepharon.</p><p><strong>Methods: </strong>Retrospective, observational case series. Thirty-nine patients (40 eyes) were included, all with severe recurrent pterygium with symblepharon. During surgery, CBS was employed to affix large autologous conjunctival grafts to the exposed sclera, aiming to restore the ocular surface to smoothness as much as possible. All patients were followed up for more than one year. Main outcome measures include the rate of recurrence, improvement of eye movement, and intraoperative and postoperative complications.</p><p><strong>Results: </strong>Nearly all patients exhibited a smooth ocular surface and largely restored physiological structures during the follow-up period. There were no graft loss or contraction cases until the last follow-up, with only three eyes experiencing a pterygium recurrence (recurrence rate 7.5%, 3/40). Preoperative eye movement limitations improved significantly from 2.10 ± 0.71 (range 1-3) to 0.33 ± 0.53 (range 0-2; <i>p</i> < 0.001) post-surgery. Other postoperative complications included varying degrees of corneal scarring and a single instance of conjunctival granulomatous hyperplasia (1 eye, 2.5%).</p><p><strong>Conclusion: </strong>When addressing severe recurrent pterygium with Symblepharon, using CBS to secure large autologous conjunctival grafts during surgery can achieve favorable postoperative outcomes. This surgical method is safe and feasible and effectively rebuilds a smooth ocular surface, improves the appearance of the ocular surface, and reduces the recurrence rate of pterygium after excision.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"16 ","pages":"25158414241294191"},"PeriodicalIF":2.3,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08eCollection Date: 2024-01-01DOI: 10.1177/25158414241294022
Sonali Dave, Lee Jones, Matthew Lee, Lara Ditzel-Finn, Claire Castle, Nikki Heinze, Judith Potts, Mariya Moosajee, Renata S M Gomes
Background: Charles Bonnet syndrome (CBS) refers to the experience of visual hallucinations occurring secondary to sight loss. Although there is an increasing amount of research on this phenomenon, CBS remains a lesser-known outcome of visual impairment, with limited research into the impact on the patient.
Objectives: To explore the experiences and opinions of visually impaired military veterans with CBS regarding the impact of visual hallucinations.
Design: Semi-structured qualitative interviews.
Methods: Forty-six telephone interviews were conducted with members of Blind Veterans UK, a charity for visually impaired ex-service men and women. One-hundred and fifteen individuals at the charity with CBS were identified and invited to a semi-structured interview (participation rate - 40%). Qualitative data was transcribed and analysed using thematic analysis.
Results: Four overarching themes were identified: (1) impact of CBS (2) understanding and management of CBS (3) awareness of CBS (4) recommendations. Negative impact of CBS included feelings of fear, annoyance and disruptions to daily life and quality of life. Negative appraisal of CBS was not necessarily related to negative hallucination content. Participants expressed the value of increased awareness amongst patients and health care professionals. Knowledge and understanding of CBS provided reassurance and was considered an effective strategy to mitigate the negative impact of the condition.
Conclusion: Regardless of hallucination content, CBS has a substantial impact on the lives of people with visual impairment. Increased awareness and information can help to support individuals to manage their CBS more effectively. However, the findings from this study cannot be generalized to people without a military background so further research is required to understand and optimize support for military veterans and civilians with CBS.
背景:查尔斯-波奈综合征(Charles Bonnet syndrome,CBS)是指因视力丧失而产生的视觉幻觉。尽管对这一现象的研究越来越多,但 CBS 仍是一种鲜为人知的视力障碍结果,对患者影响的研究也很有限:目的:探讨患有 CBS 的视力受损退伍军人对视幻觉影响的体验和看法:设计:半结构式定性访谈:对英国盲人退伍军人组织(Blind Veterans UK)的成员进行了 46 次电话访谈,该组织是一个为视力受损的退伍军人服务的慈善机构。该慈善机构确定了 115 名患有 CBS 的个人,并邀请他们参加半结构化访谈(参与率为 40%)。采用主题分析法对定性数据进行转录和分析:结果:确定了四大主题:(1) CBS 的影响 (2) 对 CBS 的理解和管理 (3) 对 CBS 的认识 (4) 建议。CBS 的负面影响包括恐惧感、烦扰感以及对日常生活和生活质量的干扰。对 CBS 的负面评价并不一定与负面幻觉内容有关。参与者表示,提高患者和医护人员对 CBS 的认识很有价值。对 CBS 的了解和认识可让患者安心,并被认为是减轻该病症负面影响的有效策略:无论幻觉内容如何,CBS 都会对视力障碍患者的生活产生重大影响。提高对 CBS 的认识并增加相关信息,有助于帮助他们更有效地管理自己的 CBS。然而,这项研究的结果不能推广到没有军队背景的人身上,因此需要进一步研究,以了解并优化对患有 CBS 的退伍军人和平民的支持。
{"title":"The experiences of visually impaired military veterans with Charles Bonnet syndrome.","authors":"Sonali Dave, Lee Jones, Matthew Lee, Lara Ditzel-Finn, Claire Castle, Nikki Heinze, Judith Potts, Mariya Moosajee, Renata S M Gomes","doi":"10.1177/25158414241294022","DOIUrl":"https://doi.org/10.1177/25158414241294022","url":null,"abstract":"<p><strong>Background: </strong>Charles Bonnet syndrome (CBS) refers to the experience of visual hallucinations occurring secondary to sight loss. Although there is an increasing amount of research on this phenomenon, CBS remains a lesser-known outcome of visual impairment, with limited research into the impact on the patient.</p><p><strong>Objectives: </strong>To explore the experiences and opinions of visually impaired military veterans with CBS regarding the impact of visual hallucinations.</p><p><strong>Design: </strong>Semi-structured qualitative interviews.</p><p><strong>Methods: </strong>Forty-six telephone interviews were conducted with members of Blind Veterans UK, a charity for visually impaired ex-service men and women. One-hundred and fifteen individuals at the charity with CBS were identified and invited to a semi-structured interview (participation rate - 40%). Qualitative data was transcribed and analysed using thematic analysis.</p><p><strong>Results: </strong>Four overarching themes were identified: (1) impact of CBS (2) understanding and management of CBS (3) awareness of CBS (4) recommendations. Negative impact of CBS included feelings of fear, annoyance and disruptions to daily life and quality of life. Negative appraisal of CBS was not necessarily related to negative hallucination content. Participants expressed the value of increased awareness amongst patients and health care professionals. Knowledge and understanding of CBS provided reassurance and was considered an effective strategy to mitigate the negative impact of the condition.</p><p><strong>Conclusion: </strong>Regardless of hallucination content, CBS has a substantial impact on the lives of people with visual impairment. Increased awareness and information can help to support individuals to manage their CBS more effectively. However, the findings from this study cannot be generalized to people without a military background so further research is required to understand and optimize support for military veterans and civilians with CBS.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"16 ","pages":"25158414241294022"},"PeriodicalIF":2.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}